Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy

International Journal of Cancer

Volumn 136, Issue 5, 2015, Pages E387-E395

  Aarts, Mieke J ^a   Van Den Borne, Ben E ^b   Biesma, Bonne ^c   Kloover, Jeroen S ^d   Aerts, Joachim G ^e,f   Lemmens, Valery E P P ^a,f  

^a Eindhoven   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

^d TweeSteden Hospital   (Netherlands)

^e AMPHIA HOSPITAL   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Non small cell lung cancer; Population based; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HUMAN; LIVER METASTASIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POPULATION RESEARCH; QUALITY OF LIFE; SOCIAL STATUS; SURVIVAL RATE; ADENOCARCINOMA; CANCER GRADING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COMPARATIVE STUDY; FOLLOW UP; LUNG NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; TUMOR INVASION;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; NETHERLANDS; PROGNOSIS; SURVIVAL RATE;

EID: 84918789215     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29216     Document Type: Article

References (37)

1. International Agency for Research on Cancer. Globocan. http://globocan. iarc.fr/Pages/fact-sheets-population.aspx, 2012. Accessed September 24, 2014.
2. Netherlands Cancer Registry, 2014. Available at: www.cijfersoverkanker.nl. Accessed September 24, 2014.
3. Working Group Treatment Lung Cancer, [Factsheet Lung Cancer], 2012.
4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Nonsmall Cell Lung Cancer Collaborative Group. BMJ (Clinical research ed) 1995;311:899-909.
5. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and metaanalysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-25.
6. Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced nonsmall cell lung cancer: improved survival without detriment to quality of life. Thorax 2004;59:828-36.
7. Oncoline. Available at: wrichtlijn. Accessed October 29, 2013
8. Earle CC, Neumann PJ, Gelber RD, et al. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 2002;20:1786-92.
9. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000;117:1239-46.
10. Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 2004;22:4971-8.
11. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2191-7.
12. Chrischilles EA, Pendergast JF, Kahn KL, et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 2010;28:620-7.
13. Rasco DW, Yan J, Xie Y, et al. Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol 2010;5:1529-35.
14. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. 3rd edn. Geneva: World Health Organization 2000.
15. Sobin L, Wittekind C. UICC International Union against Cancer. TNM Classification of malignant tumours, 6th edn. Geneva, Switzerland: Wiley-Liss, 2002.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83.
17. Van Duin C, Keij I. Sociaal-economische status indicator op postcodeniveau [in Dutch]. Maandstatistiek van de bevolking 2002;50:32-35.
18. Schouten LJ, Hoppener P, Van Den Brandt PA, et al. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 1993;22:369-76.
19. NSCLC Meta-analysis Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and metaanalysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-25.
20. Patel N, Adatia R, Mellemgaard A, et al. Variation in the use of chemotherapy in lung cancer. Br J Cancer 2007;96:886-90.
21. Forrest LF, Adams J, Wareham H, et al. Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis. PLoS Med 2013;10:e1001376.
22. Berglund A, Lambe M, Luchtenborg M, et al. Social differences in lung cancer management and survival in South East England: a cohort study. BMJ open 2012;2.
23. Louwman WJ, Aarts MJ, Houterman S, et al. A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status. Br J Cancer 2010;103:1742-48.
24. Vinod SK, O'Connell DL, Simonella L, et al. Gaps in optimal care for lung cancer. J Thorac Oncol 2008;3:871-9.
25. Jacob S, Hovey E, Ng W, et al. Estimation of an optimal chemotherapy utilisation rate for lung cancer: an evidence-based benchmark for cancer care. Lung Cancer 2010;69:307-14.
26. Orde van Medisch Specialisten, Vereniging van Integrale Kankercentra, Kwaliteitsinstituut voor de Gezondheidszorg. Guideline Non-Small Cell Lung Cancer: staging and treatment [in Dutch]ed. Alphen aan den Rijn: Van Zuiden Communications, 2004.
27. Bernards N, Creemers GJ, Nieuwenhuijzen GA, et al. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol 2013;24:3056-60.
28. Comprehensive Cancer Centre the Netherlands. Online. Treatment guideline brain metastases [in Dutch only], vol. 2013, 2011. http://www.oncoline.nl/richtlijn/item/index.php?pagina=/richtlijn/item/pagina.php&richtlijn-id=670
29. Davidoff AJ, Gardner JF, Seal B, Edelman MJ. Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced nonsmall cell lung cancer. J Thorac Oncol 2011;6:934-41.
30. Blinman P, Alam M, Duric V, et al. Patients' preferences for chemotherapy in non-small-cell lung cancer: a systematic review. Lung Cancer 2010;69:141-7.
31. Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012;367:1616-25.
32. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced nonsmallcell lung cancer. J Clin Oncol 2009;27:591-8.
33. Effects of vinorelbine on quality of life and survival of elderly patients with advanced nonsmallcell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999;91:66-72.
34. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
35. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant nonsmall cell lung cancers. Lung Cancer 2007;58:95-103.
36. Van Herk-Sukel MP, Van De Poll-Franse LV, Lemmens VE, et al. New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer 2010;46:395-404.
37. ZonMw. ZonMw Doelmatigheidsonderzoek. PET gepast gebruik (t) [in Dutch] 2007.